Loading…
Metabolic defects shared by Alzheimer's disease and diabetes: A focus on mitochondria
Type 2 diabetes (T2D) and Alzheimer's disease (AD) are two global epidemics that share several metabolic defects, such as insulin resistance, impaired glucose metabolism, and mitochondrial defects. Importantly, strong evidence demonstrates that T2D significantly increases the risk of cognitive...
Saved in:
Published in: | Current opinion in neurobiology 2023-04, Vol.79, p.102694-102694, Article 102694 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Type 2 diabetes (T2D) and Alzheimer's disease (AD) are two global epidemics that share several metabolic defects, such as insulin resistance, impaired glucose metabolism, and mitochondrial defects. Importantly, strong evidence demonstrates that T2D significantly increases the risk of cognitive decline and dementia, particularly AD. Here, we provide an overview of the metabolic defects that characterize and link both pathologies putting the focus on mitochondria. The biomarker potential of mitochondrial components and the therapeutic potential of some drugs that target and modulate mitochondria are also briefly discussed.
•Type 2 diabetes (T2D) is an important risk factor for Alzheimer's disease (AD).•Mitochondrial dysfunction is a shared feature between T2D and AD.•Mitochondrial components found in peripheral blood are potential biomarkers of neurodegeneration.•Mitochondria-targeted drugs have the potential to treat neurodegenerative conditions. |
---|---|
ISSN: | 0959-4388 1873-6882 |
DOI: | 10.1016/j.conb.2023.102694 |